Highlights of This Issue 937

SPECIAL FEATURES

CCR 20th Anniversary Commentary

939 CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
   Beverly A. Teicher and Kenneth C. Anderson

942 CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
   Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Waes

CCR Translations

944 Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
   Roxana S. Dronca and Haidong Dong
   See related articles, p. 1115 and p. 1127

947 Moving from Evaluation to Value in Cancer Care
   Richard L. Schilsky
   See related article, p. 1036

CCR Perspectives in Drug Approval

950 FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
   Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeannie F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrke, Robert Justice, Ann Farrell, and Richard Pazdur

Molecular Pathways

955 Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
   Rebecca A. Prieve, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood

962 Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
   Hae-Yun Jung, Lauren Fattet, and Jing Yang

Reviews

969 Zebrafish: A New Companion for Translational Research in Oncology
   Jorge Barriuso, Raghavendar Nagaraju, and Adam Hurlstone

976 Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
   Valsamo K. Anagnostou and Julie R. Brahmer

CANCER THERAPY: CLINICAL

985 A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

995 CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
   Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gamlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domchek, Kerrihi Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer

1002 Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

1010 Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing’s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam

Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy

Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhenghua Liu, Song Liu, Ben Wang, Qi Sun, WeiBo Niu, Enyu Liu, Bayong Wang, and Jun Niu

Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahilberg, Giulia Bottai, Bjørn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Maréchal, Jean-Baptiste Bachi, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svcek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Tref, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.